Screening


to Christina Burtsoff Asp, Marketing Manager, GE Healthcare Life Sciences, Sweden – Biacore™ 4000 for candidate selection and Biacore™ T200 for characterisation of biomolecular interactions. Biacore™ 4000 is designed for confident candi- date selection in biotherapeutic and small molecule drug discovery. It is developed for large-scale paral- lel interaction analyses, with the capability to analyse up to 4,800 interactions in 24 hours. The system provides high quality binding, kinetic, affini- ty, concentration and specificity data in both screen- ing assays and detailed characterisation studies. Biacore™ T200 is a versatile, label-free interac- tion analysis system with outstanding sensitivity for comprehensive characterisation of biomolecu- lar interactions. The system pushes the detection limits in label-free analysis by enabling new appli- cations such as GPCRs, offering increased assay flexibility and providing more confidence in data from early research to drug discovery and develop- ment, and on to QC.


“Label-free technologies including surface plas- mon resonance (SPR) and isothermal titration calorimetry (ITC) are increasingly being used in


drug discovery and development, providing key insights into biological process and molecular binding mechanisms,” says Burtsoff Asp. “The use of biophysical methods is becoming more and more important in fragment-based drug discovery and vaccine development, demanding increased sensitivity, reproducibility and improved data pro- cessing. GE Healthcare Life Sciences’ newly launched products within label-free interaction analysis address these needs enabling better- informed decisions earlier. Similarly, label-free technologies for small organism imaging and analysis will allow phenotypic screening at the organ level, complementing the molecular-level insights allowed by SPR and ITC.”


Roche Diagnostics Roche’s (www.roche.com) flagship label-free tech- nology is the xCELLigence™ system, according to Steven Hurwitz, Manager of Marketing, Cellular Systems at Roche Diagnostics Corporation. New for 2011 is the xCELLigence™ RTCA HT instrument that offers a modular 384-well format where up to four plate stations can be run on a


Address Even the Most Di cult Assays


RapidFire®enables label-free detec on of na ve analytes for previously intractable targets


Label-free screening for:


• oncology • epigene cs • metabolic disorders • cardiovascular disease • an -infec ves • neurological disorders • in amma on


T: 781.721.3695 | F: 781.998.0054 | www.BIOCIUS.com | info@biocius.com Drug Discovery World Winter 2010/11 43


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80